If the FDA approves Biogen’s Alzheimer’s treatment, I won’t prescribe it

You might think that I’m among those hoping the FDA will approve aducanumab, an experimental Alzheimer’s drug developed by Biogen, a decision the agency is supposed to make by June 7.

But I’m not. And if it gets the green light, I can’t see myself recommending it to my patients. Colleagues of mine in the Alzheimer’s sphere are also reluctant about approving aducanumab. Why? Biogen hasn’t made a convincing case for it.